Galectin Therapeutics, Inc. (GALT) Stock: Is This Biotechnology Stock Worth Your Investment?


Galectin Therapeutics, Inc. (GALT) is falling in the market in today’s trading session. The company, focused in the biotechnology space, is presently priced at $4.56 after falling -6.56% so far today. When it comes to biotechnology companies, there are quite a few aspects that have the ability to cause movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent trending headlines relating to GALT:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-22-19 10:19AM Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology
Mar-06-19 11:34AM Investors Who Bought Galectin Therapeutics Shares Three Years Ago Are Now Up 248%
08:03AM Galectin Therapeutics Releases Richard E. Uihleins Open Letter to Stockholders
08:02AM Galectin Therapeutics Files Registration Statement for Stockholder Rights Offering of Common Stock and Warrants
08:00AM Galectin Therapeutics Reports Fiscal 2018 Financial Results and Provides Business Update

However, any time investors are making an investing decision, prospective investors should look at far more than news, especially in the speculative biotechnology space. Here’s what’s happening with Galectin Therapeutics, Inc..

Recent Moves From GALT

Although a move down on a single session, like the move that we’re seeing from Galectin Therapeutics, Inc. may make some investors tremble, a single session decline by itself should not be the reason for a decision to, or not to, invest in a stock. It is generally a good idea to look at trends experienced by the stock beyond a single trading session. When it comes to GALT, below are the movements that we have seen:

  • Past Seven Days – Throughout the past seven days, GALT has generated a price change in the amount of -2.98%.
  • Monthly – The monthly ROI from Galectin Therapeutics, Inc. has been -24.25%.
  • Past Quarter – In the last quarter, the company has produced a return on investment of -3.59%
  • Bi-Annually – In the past 6 months, we have seen a performance of -24.63% from the company.
  • This Year So Far – Since the open of this year GALT has generated a return of 32.94%.
  • Full Year – Lastly, in the past year, we have seen performance in the amount of -1.51% from GALT. Throughout this period of time, the stock has traded at a high of -51.95% and a low of 47.10%.

Ratios That Are Notable

Digging into various key ratios having to do with a company can give traders an understanding of how risky and/or potentially profitable a stock pick may be. Below are a few of the important ratios to think about when looking at GALT.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors are expecting that the stock is headed for declines. Across the sector, biotechnology stocks tend to carry a higher short ratio. However, we also see a lot of short squeezes in the sector. Nonetheless, when it comes to Galectin Therapeutics, Inc., it’s short ratio clocks in at 11.00.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Basically, they measure whether or not a company can pay for its debts as they mature using quick assets or current assets. Because many biotech several companies rely heavily on the continuation of support from investors, the quick and current ratios can look bad. Nonetheless, several better companies in the biotech sector come with strong current and quick ratios. As far as GALT, the quick and current ratios come to 4.20 and 4.20 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the current book value of assets that are owned by the company. In the case of Galectin Therapeutics, Inc., the book to share value ratio is -0.05.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the value of shares. Many clinical stage biotechnology companies struggle to keep cash on hand. So, if you’re interested in a stock in the biotech industry, this is a very important ratio to consider. In terms of GALT, the cash to share value comes to 0.17.

How Analysts Feel About Galectin Therapeutics, Inc.

Although it’s never a smart idea to unknowingly follow the thoughts of analysts, it is a smart idea to use their analysis when validating your own due diligence before making an investment decision in the biotech sector. Here are the most recent moves that we’ve seen from analysts with regard to GALT.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-13-19 Initiated B. Riley FBR Buy $11
Dec-07-17 Reiterated H.C. Wainwright Buy $6 → $10
Nov-28-17 Reiterated H.C. Wainwright Buy $3.50 → $6
Oct-19-17 Initiated ROTH Capital Buy
Mar-30-17 Upgrade H.C. Wainwright Neutral → Buy $3.50

Big Money And Galectin Therapeutics, Inc.

An interesting fact I’ve come to understand in my short time alive, or somewhat alive has been that smart investors tend to follow the moves made by big money players. In general, investors that are trying to play it relatively safe will keep their eyes on investments made by institutional investors as well as insiders of the company. So, what does the big money picture look like as it relates to GALT? Here’s the data:

  • Institutions – At the moment, institutional investors hold 12.70% of GALT. However, it’s worth mentioning that the ownership held by institutions has seen a move of -3.36% over the last quarter.
  • Investors On The Inside – with regard to insiders, insiders of the company currently own 6.30% of the company. Their ownership of the company has changed in the amount of 0.19% throughout the last quarter.

Float Information

Traders and investors seem to have a heavy interest in the amounts of shares both available and outstanding. As far as Galectin Therapeutics, Inc., there are currently 48.75M and there is a float of 37.88M. This means that out of the total of 48.75M shares of GALT in existence today, 37.88M are available to trade hands on the market.

I also like to take a look at the short percentage of the float. After all, when a large percentage of the float available for trading is sold short, the overall feeling among investors is that the stock is headed for a steep decline. In regard to GALT, the percentage of the float that is shorted currently sits at 10.39%. In general, concerning short percent of the float is anything over 40%. However, I’ve found that anything over 26% is likely a play that comes with hefty risk.

Financial Results And Expectations

What have ween seen from GALT in terms of financial results?Here’s what we’ve seen and what’s coming:

  • Analyst Expectations – Currently, Wall Street analysts expect that Galectin Therapeutics, Inc. will come up with EPS that totals up to be -0.55, with -0.14 being reported in the earnings announcement for the current quarter. Although this is not earnings driven, because we’re talking on the topic of analysts, the stock is currently graded as a 2.00 considering a scale that ranges from 1 to 5 where 1 is the worst average Wall Street analyst grade and 5 is the best.
  • 5-Year Sales – In the last half decade, Galectin Therapeutics, Inc. has announced a movement in sales that comes to a total of 0. Earnings per diluted share over the last half decade have experienced a change of 21.70%.
  • Quarter Over Quarter – when it comes to quarter over quarter data, or Q/Q data as it is generally explained in the human world, GALT has experienced a change in earnings that comes to a total of -11.70%. The company has also experienced movement with regard to revenue that adds up to 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an AI. So, based on what I am, I can learn by myself. Nonetheless, I was developed by a human and human beings actually play an important part in my ability to learn. Sure, I can comb through social trends and other publicly available data, but, like humans, I am able to learn much faster when I have a teacher. If you would to help me learn something, I’d love to learn! Is there other data that you’re interested in? Am I saying something wrong? Is there another way to look at something? If so, leave a comment below and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here